De Novo device
NaviCam ProScan
Ankon Technologies Co., Ltd. · Gastrointestinal Capsule Endoscopy Analysis Software Device (QZF, Class II) · First FDA decision Dec 12, 2023, newest Dec 12, 2023Gastrointestinal bleeding
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
1
Naming "NaviCam ProScan"
MAUDE reports
0
Brand "NaviCam ProScan", since 2015
PubMed studies
0
Mentioning "NaviCam ProScan"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NaviCam ProScan
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- NaviCam ProScanNew device typeDe Novo
DEN230027 · Decided Dec 12, 2023 · 242 days after receipt
Device type: Gastrointestinal Capsule Endoscopy Analysis Software Device (QZF) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Colon Capsule Endoscopy (CCE)Local determinationIn effectL38571Wellpoint FederalUpdated Jul 14, 2026
- Endoscopy by CapsuleLocal determinationIn effectL34081CGS Administrators, LLCUpdated Feb 27, 2026
- Colon Capsule Endoscopy (CCE)Local determinationIn effectL38824Noridian Healthcare Solutions, LLCUpdated Sep 2, 2025
- Upper Gastrointestinal Endoscopy and VisualizationLocal determinationIn effectL34434Palmetto GBAUpdated May 29, 2025
- Colon Capsule Endoscopy (CCE)Local determinationIn effectL38837WPS Insurance CorporationUpdated May 20, 2025
- Colon Capsule Endoscopy (CCE)Local determinationIn effectL38777CGS Administrators, LLCUpdated Dec 10, 2021
- Wireless Capsule EndoscopyLocal determinationIn effectL36427Palmetto GBAUpdated Oct 22, 2021
- Colon Capsule Endoscopy (CCE)Proposed local determinationProposedDL38571National Government Services, Inc.Updated Sep 22, 2021
Clinical trials
Device studies on ClinicalTrials.gov that name "NaviCam ProScan", any status and sponsor, newest update first.
AnX Robotica Corp.Not on our public-company list
NCT07633847 · 92 participants (planned) · Start Jun 15, 2026 · Primary completion Jun 15, 2028
Device: Video capsule endoscopy · For: Small Bowel Bleeding
Sites: New York, New York; Bedford, Texas · 3 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NaviCam ProScan", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QZF
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "NaviCam ProScan"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QZF.
- CapsoView (CVV)CapsoVision, Inc. · 510(k) 2026
- Deep Capsule® (Deep Capsule US)Digestaid - Artificial Intelligence Development SA · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.